Respire 1: A phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis

European Respiratory Journal

Volumn 51, Issue 1, 2018, Pages

  De Soyza, Anthony ^a   Aksamit, Timothy ^b   Bandel, Tiemo Joerg ^c   Criollo, Margarita ^d   Stuart Elborn, J ^e   Operschall, Elisabeth ^c   Polverino, Eva ^f   Roth, Katrin ^c   Winthrop, Kevin L ^g   Wilson, Robert ^e  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b MAYO CLINIC   (United States)

^c BAYER AG   (Germany)

^d Bayer Inc   (Canada)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; PLACEBO; ANTIINFECTIVE AGENT;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHIECTASIS; BRONCHOSPASM; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY POWDER; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; HAZARD RATIO; HEADACHE; HEMOPTYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NON CYSTIC FIBROSIS BRONCHIECTASIS; OROPHARYNX PAIN; OSTEOARTHRITIS; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINUSITIS; TENDINITIS; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECT; DRY POWDER INHALER; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; POWDER; PROPORTIONAL HAZARDS MODEL; PSEUDOMONAS AERUGINOSA;

ADMINISTRATION, INHALATION; AGED; ANTI-BACTERIAL AGENTS; BRONCHIECTASIS; CIPROFLOXACIN; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRY POWDER INHALERS; FEMALE; HUMANS; MALE; MIDDLE AGED; POWDERS; PROPORTIONAL HAZARDS MODELS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TREATMENT OUTCOME;

EID: 85045712871     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.02052-2017     Document Type: Article

References (20)

1. Chalmers JD, Smith MP, McHugh BJ, et al. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2012; 186: 657–665.
2. Chalmers JD, Goeminne P, Aliberti S, et al. The Bronchiectasis Severity Index. An international derivation and validation study. Am J Respir Crit Care Med 2014; 189: 576–585.
3. Vendrell M, de Gracia J, Olveira C, et al. Diagnostico y tratamiento de las bronquiectasias. SEPAR. [Diagnosis and treatment of bronchiectasis. Spanish Society of Pneumology and Thoracic Surgery.] Arch Bronconeumol 2008; 44: 629–640.
4. Chang AB, Bell SC, Byrnes CA, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. Med J Aust 2010; 193: 356–365.
5. Pasteur MC, Bilton D, Hill AT, et al. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010; 65: Suppl. 1, 1–58.
6. Weers J, Tarara T. The PulmoSphere™ platform for pulmonary drug delivery. Ther Deliv 2014; 5: 277–295.
7. Stass H, Nagelschmitz J, Kappeler D, et al. Ciprofloxacin dry powder for inhalation in patients with noncystic fibrosis bronchiectasis or chronic obstructive pulmonary disease, and in healthy volunteers. J Aerosol Med Pulm Drug Deliv 2017; 30: 53–63.
8. Wilson R, Welte T, Polverino E, et al. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J 2013; 41: 1107–1115.
9. Aksamit T, Bandel TJ, Criollo M, et al. The RESPIRE trials: two phase III, randomised, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis. Contemp Clin Trials 2017; 58: 78–85.
10. Lo D, VanDevanter DR, Flume P, et al. Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent? Respir Med 2011; 105: Suppl. 2, S9–S17.
11. Barker AF, O’Donnell AE, Flume P, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised, double-blind, placebo-controlled phase 3 trials. Lancet Respir Med 2014; 2: 738–749.
12. Haworth CS, Wanner A, Froehlich J, et al. Inhaled liposomal ciprofloxacin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection: results from two parallel phase III trials (ORBIT-3 and -4)). Multidiscip Respir Med 2018; in press.
13. Wilson CB, Jones PW, O’Leary CJ, et al. Validation of the St. George’s Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med 1997; 156: 536–541.
14. McCambridge J, Witton J, Elbourne DR. Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J Clin Epidemiol 2014; 67: 267–277.
15. Stass H, Delesen H, Nagelschmitz J, et al. Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study. J Aerosol Med Pulm Drug Deliv 2015; 28: 106–115.
16. Flume PA. A role for aerosolized antibiotics. Pediatr Pulmonol 2008; 43: S29–S34.
17. de la Rosa D, Martinez-Garcia MA, Olveira C, et al. Annual direct medical costs of bronchiectasis treatment: impact of severity, exacerbations, chronic bronchial colonization and chronic obstructive pulmonary disease coexistence. Chron Respir Dis 2016; 13: 361–371.
18. Brodt AM, Stovold E, Zhang L. Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review. Eur Respir J 2014; 44: 382–393.
19. Hill AT, Haworth CS, Aliberti S, et al. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. Eur Respir J 2017; 49: 1700051.
20. Martinez-Garcia MA, de Gracia J, Vendrell Relat MV, et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J 2014; 43: 1357–1367.